Table 3 Course and outcome of danaparoid treatment
From: Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT
Patient | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
Danaparoid initiation –Days after admission | 1 | 6 | 2 | 0 | 0 | 4 |
Route of administration | iv | sc | sc | sc | sc | sc |
Initial sc. daily dose (U) | No | 2500 | 1500 | 3000 | N/A | N/A |
Anti-FXa (U/mL) Median | 0.23 | 0.31 | 0.33 | 0.23 | N/A | N/A |
D-Dimer after 4–7 days of danaparoid therapy | N/A | 1.7 | 11.8 | 1.9 | 5.2 | N/A |
Bleeding events | Yes* | No | No | No | No | No |
Outcome | Fatal | Recovery | Recovery | Recovery | Recovery | Recovery |